Dr. Mark McCamish serves as President, Chief Executive Officer & Board Member at Forty Seven. He is also an angel investor. He is an international expert in biosimilars and biologics. Mark is passionate about mentoring and developing people while focusing on meeting patient needs through efficient, commercially viable efforts. He is a senior executive with extensive experience at multiple companies including Protein Design Labs, Abbott, Amgen and Novartis-Sandoz. He led pioneering efforts in filing and launching biosimilars worldwide. He has demonstrated a commercial mindset in establishing research and development strategies leading to approvals and commercial success in multiple therapeutic areas and regulatory categories including biologics, biosimilars, drugs, devices and medical foods. He held professorships at the University of California, Davis and The Ohio State University. After completing his Ph.D. in Nutritional Sciences from Penn State and M.D. from the University of California, Los Angeles, he completed Residency and Fellowship Training at the University of California, Davis. Mark received his Bachelor's and Master's degrees from University of California, Santa Barbara.